DYAI - Dyadic International, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1800
+0.0100 (+0.46%)
At close: 03:59PM EDT
2.0800 -0.10 (-4.59%)
After hours: 05:45PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.1700
Open2.1600
Bid0.0000 x 800
Ask0.0000 x 2200
Day's Range2.1600 - 2.2600
52 Week Range1.1200 - 3.5600
Volume10,492
Avg. Volume38,930
Market Cap62.808M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.2800
Earnings DateAug 08, 2023 - Aug 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DYAI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Dyadic to Participate at Upcoming Events in June

    JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participa

  • Simply Wall St.

    Dyadic International (NASDAQ:DYAI) shareholders are up 12% this past week, but still in the red over the last three years

    While not a mind-blowing move, it is good to see that the Dyadic International, Inc. ( NASDAQ:DYAI ) share price has...

  • Zacks Small Cap Research

    DYAI: Abundant Opportunities in Products and Animal & Human Health

    By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT First Quarter 2023 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) provided 2022 operational and financial results in a press release on May 10, 2023, filed its Form 10-Q with the SEC and held a conference call with investors. Dyadic announced several new collaborations and expanded agreements

  • GlobeNewswire

    Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

    New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop, manufacture and commercialize affordable vaccines and biologics for human and animal health for African ContinentExpanded collaboration with Phibro/Abic animal health to develop vaccines for animal diseasesFully funded co-development and marketing agreement with Fermbox to use Dapibus™ platform to develop a

  • GlobeNewswire

    Dyadic to Participate at Two Industry Events in May

    JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that they will be participating in the following events during the month of May. PEGS Boston Conf

  • GlobeNewswire

    Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™

    JUPITER, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a co-development and marketing a

  • GlobeNewswire

    Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

    JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a

  • GlobeNewswire

    Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform

    JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a Notice of Allowance from

  • GlobeNewswire

    Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent

    JUPITER, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced it signed an expanded licensing agreement for its C1-cell

  • Insider Monkey

    Dyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call Transcript

    Dyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Good evening, and welcome to Dyadic International’s Fiscal Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management’s prepared remarks, there will be a brief question-and-answer session. As a reminder, this conference is being recorded today, […]

  • Simply Wall St.

    Dyadic International Full Year 2022 Earnings: Revenues Disappoint

    Dyadic International ( NASDAQ:DYAI ) Full Year 2022 Results Key Financial Results Revenue: US$2.93m (up 22% from FY...

  • Zacks Small Cap Research

    DYAI: 2022 Results

    By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) provided 2022 operational and financial results in a press release on March 29, 2023, filed its Form 10-K with the SEC and held a conference call with investors. Dyadic has advanced to the next stage of a development company with C1 derived proteins evaluated in human subjects in the

  • GlobeNewswire

    Dyadic to Present at World Vaccine Congress Washington 2023

    JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccin

  • GlobeNewswire

    Dyadic Reports 2022 Year End Results and Recent Company Progress

    Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate which has completed dosing of all patients in both the low and high dose testing groupsOngoing research and license agreements with Janssen, Hengrui, NIIMBL and others for the C1-expressed therapeutic proteins for human health Expanded collaboration with Phibro/Abi

  • GlobeNewswire

    Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

    JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it will report its financial results for the year ended 2022 and host a corporate upda

  • Simply Wall St.

    Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

    Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 JUPITER, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction

  • GlobeNewswire

    Dyadic to Present at Roth Investor Conference and Upcoming Industry Events

    JUPITER, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its management and business partners from VTT Technical Research Centre of Finland Ltd, wi

  • GlobeNewswire

    Dyadic to Participate in Two Upcoming Investor Conferences

    JUPITER, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be participating in the following two upcom

  • Zacks Small Cap Research

    DYAI: First Patient Administered C1 Derived Vaccine

    By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) achieved a pivotal point in its maturation as a provider of therapeutic proteins as it and partner Rubic One Health dosed its first patient with DYAI-100, a COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate. This is an important milestone as

  • GlobeNewswire

    Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

    JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced during management’s Q3 earnings call, it has initiated dosing in its Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the DYAI-100 COVID-19 recombinant protein re

  • GlobeNewswire

    Dyadic Announces Sale of Equity Interest in Alphazyme

    JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it received approximately $1.27 million in connection with the sale of its equity interest in Alphazyme LL

  • GlobeNewswire

    Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference

    Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA USAJUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effect

  • GlobeNewswire

    Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

    “Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s anticipated First-In-Human clinical trial designed to demonstrate clinical safety and immune response in humans for its DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidate.The C1-cell produced RBD-C-tag antigen strongly binds ACE2 receptors in vitro. Adjuvanted RBD-C-tag-based vaccine ca

  • Zacks Small Cap Research

    DYAI: DYAI-100 Phase I in the Spotlight

    By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Third Quarter 2022 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) provided third quarter 2022 operational and financial results in a press release on November 10, 2022, filed its Form 10-Q with the SEC and hosted a conference call with investors. Dyadic is more explicitly orienting its efforts